ACE-Inhibition and Physical Function: Results From the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) Study

Journal of the American Medical Directors Association

Volumn 11, Issue 1, 2010, Pages 26-32

  Cesari, Matteo ^a,b   Pedone, Claudio ^a   Antonelli Incalzi, Raffaele ^a   Pahor, Marco ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ACE inhibition; Fosinopril; muscle strength; physical function

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; FOSINOPRIL; PLACEBO;

ADULT; AGED; ARTICLE; BODY EQUILIBRIUM; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; FEMALE; GRIP STRENGTH; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE; WALKING SPEED;

EID: 73249136316     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2009.09.014     Document Type: Article

References (42)

1. Guralnik J.M., Fried L.P., and Salive M.E. Disability as a public health outcome in the aging population. Annu Rev Public Health 17 (1996) 25-46
2. Pahor M., Blair S.N., Espeland M., et al. Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. J Gerontol A Biol Sci Med Sci 61 (2006) 1157-1165
3. Carter C.S., Onder G., Kritchevsky S.B., and Pahor M. Angiotensin-converting enzyme inhibition intervention in elderly persons: effects on body composition and physical performance. J Gerontol A Biol Sci Med Sci 60 (2005) 1437-1446
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
5. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
6. Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (1998) 645-652
7. Tatti P., Pahor M., Byington R.P., et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21 (1998) 597-603
8. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
9. Coirault C., Langeron O., Lambert F., et al. Impaired skeletal muscle performance in the early stage of cardiac pressure overload in rabbits: beneficial effects of angiotensin-converting enzyme inhibition. J Pharmacol Exp Ther 291 (1999) 70-75
10. Coirault C., Hagege A., Chemla D., et al. Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure. Chest 119 (2001) 1755-1760
11. Onder G., Penninx B.W., Balkrishnan R., et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: An observational study. Lancet 359 (2002) 926-930
12. Sumukadas D., Witham M.D., Struthers A.D., and McMurdo M.E. Effect of perindopril on physical function in elderly people with functional impairment: A randomized controlled trial. CMAJ 177 (2007) 867-874
13. Carter C.S., Cesari M., Ambrosius W.T., et al. Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J Gerontol A Biol Sci Med Sci 59 (2004) 416-423
14. Sumukadas D., Struthers A.D., and McMurdo M.E. Sarcopenia-a potential target for angiotensin-converting enzyme inhibition?. Gerontology 52 (2006) 237-242
15. Bauer J.M., Kaiser M.J., and Sieber C.C. Sarcopenia in nursing home residents. J Am Med Dir Assoc 9 (2008) 545-551
16. Yeh S.S., Lovitt S., and Schuster M.W. Pharmacological treatment of geriatric cachexia: Evidence and safety in perspective. J Am Med Dir Assoc 8 (2007) 363-377
17. Bahi L., Koulmann N., Sanchez H., et al. Does ACE inhibition enhance endurance performance and muscle energy metabolism in rats?. J Appl Physiol 96 (2004) 59-64
18. Gray S.L., LaCroix A.Z., Aragaki A.K., et al. Angiotensin-converting enzyme inhibitor use and incident frailty in women aged 65 and older: Prospective findings from the Women's Health Initiative Observational Study. J Am Geriatr Soc 57 (2009) 297-303
19. Schellenbaum G.D., Smith N.L., Heckbert S.R., et al. Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J Am Geriatr Soc 53 (2005) 1996-2000
20. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 (2006) 2338-2345
21. Hutcheon S.D., Gillespie N.D., Crombie I.K., et al. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: A randomised double blind placebo controlled trial. Heart 88 (2002) 373-377
22. Zi M., Carmichael N., and Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 17 (2003) 133-139
23. Cranney A. Is there a new role for angiotensin-converting-enzyme inhibitors in elderly patients?. CMAJ 177 (2007) 891-892
24. Cesari M., Kritchevsky S.B., Atkinson H.H., et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: Results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J 157 (2009) 334.e1-334.e8
25. Cesari M., Kritchevsky S.B., Baumgartner R.N., et al. Sarcopenia, obesity, and inflammation-results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr 82 (2005) 428-434
26. Pahor M., Franse L.V., Deitcher S.R., et al. Fosinopril versus amlodipine comparative treatments study: A randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 105 (2002) 457-461
27. Gullestad L., Aukrust P., Ueland T., et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34 (1999) 2061-2067
28. Greenbaum R., Zucchelli P., Caspi A., et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol 49 (2000) 23-31
29. Piepho R.W. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 57 Suppl 1 (2000) S3-S7
30. Hansson L., Forslund T., Hoglund C., et al. Fosinopril versus enalapril in the treatment of hypertension: A double-blind study in 195 patients. J Cardiovasc Pharmacol 28 (1996) 1-5
31. Wagstaff A.J., Davis R., and McTavish D. Fosinopril: A reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Drugs 51 (1996) 777-791
32. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995) 1450-1456
33. Neal B., MacMahon S., and Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356 (2000) 1955-1964
34. Pahor M., Psaty B.M., Alderman M.H., et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 356 (2000) 1949-1954
35. Onder G., Penninx B.W., Lapuerta P., et al. Change in physical performance over time in older women: The Women's Health and Aging Study. J Gerontol A Biol Sci Med Sci 57 (2002) M289-M293
36. Cesari M., Penninx B.W., Pahor M., et al. Inflammatory markers and physical performance in older persons: The InCHIANTI study. J Gerontol A Biol Sci Med Sci 59 (2004) 242-248
37. Guralnik J.M., Ferrucci L., Pieper C.F., et al. Lower extremity function and subsequent disability: Consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 55 (2000) M221-M231
38. Guralnik J.M., Ferrucci L., Simonsick E.M., et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 332 (1995) 556-561
39. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: Results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 166 (2006) 659-666
40. Konstam M.A., Rousseau M.F., Kronenberg M.W., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 86 (1992) 431-438
41. Burke G.L., Arnold A.M., Bild D.E., et al. Factors associated with healthy aging: The cardiovascular health study. J Am Geriatr Soc 49 (2001) 254-262
42. Newman A.B., Arnold A.M., Naydeck B.L., et al. "Successful aging": Effect of subclinical cardiovascular disease. Arch Intern Med 163 (2003) 2315-2322